Skip to main content
SSO 2026 Annual Meeting Main banner

Genevieve M. Boland, MD, PhD (she/her/hers)

Vice Chair of Research, Surgery
Mass General Brigham
Boston, Massachusetts, United States

Genevieve M. Boland, MD, PhD, FACS is Vice Chair of Research, Surgery at Mass General Brigham (MGB), an Associate Professor of Surgery at Harvard Medical School, Program Director of Cutaneous Surgical Oncology of the MGB Cancer Institute, and the Surgical Director of the Termeer Center for Targeted Therapies at the Massachusetts General Hospital. Her primary clinical focus is on melanoma and cutaneous oncology.

She undertook combined MD/PhD training, completing a PhD in Cell and Tissue Engineering at the National Institutes of Health focusing on signaling pathways in adult, human mesenchymal stem cells. She graduated cum laude from Thomas Jefferson University as a member of the Alpha Omega Alpha medical honor society and completed her general surgical training at Massachusetts General Hospital. Following this, she completed a clinical fellowship in Complex General Surgical Oncology and a combined research fellowship at the University of Texas MD Anderson Cancer Center. She is focused on the clinical management of skin cancer patients. She is board certified in General Surgery and Complex General Surgical Oncology, and she is a Fellow of the American College of Surgeons.

Dr. Boland has received research support via many mechanisms including the American Surgical Association Foundation Fellowship, the Association of Women Surgeons Research Fellowship, the Harvard Catalyst Medical Research Investigator Training Award, the Karin Grunebaum Cancer Foundation Fellowship, the Society of Surgical Oncology Clinical Investigator Award, the Melanoma Research Foundation Breakthrough Consortium, the National Institutes of Health, the Department of Defense, and ARPA-H. She is Director of the Surgical Oncology Research Laboratories, Director of the Therapeutic Intralesional Program, and surgical lead for the MGB tumor infiltrating lymphocyte (TIL) program. She is an Associate Member of the Broad Institute of MIT and Harvard. Her laboratory is currently focused on molecular profiling of melanoma, characterization of molecular and immunological changes that occur during immunotherapy, and the identification of circulating biomarkers of cancer.

Presentation(s):